Greater Houston Retina Research

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Greater Houston Retina Research sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 7 completed early-phase tilt upper quartile by trial count

Greater Houston Retina Research: 8 sponsored US clinical trials, none currently recruiting.

Greater Houston Retina Research sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ischemic Central Retinal Vein Occlusion, with 1 trials.

Upper-quartile sponsor footprint

Greater Houston Retina Research sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 2

Safety and Efficacy of Faricimab in Patients With NPDR

NCT05681884
TERMINATED

Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema

NCT05333055
COMPLETED Phase 4

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

NCT04708145
COMPLETED Phase 2

Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement

NCT03531294
COMPLETED Phase 4

Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial

NCT02299336
COMPLETED Phase 2

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

NCT02222610
COMPLETED

New Biopsy Technique for Uveal Melanoma

NCT01924923
COMPLETED Phase 1

Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion

NCT00406471

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 4 2

Therapeutic Areas

Ischemic Central Retinal Vein Occlusion 1
Uveal Melanoma 1
Non-Proliferative Diabetic Retinopathy 1

How the Greater Houston Retina Research early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 7 completed (88%).

Phase mix: 2 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Ischemic Central Retinal Vein Occlusion (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Greater Houston Retina Research: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Greater Houston Retina Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Greater Houston Retina ResearchAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Greater Houston Retina Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Greater Houston Retina Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Greater Houston Retina Research page

8 registered trials is a research-attention snapshot, not an endorsement of Greater Houston Retina Research or any single study.

  • None of Greater Houston Retina Research's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Ischemic Central Retinal Vein Occlusion is the condition Greater Houston Retina Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ischemic Central Retinal Vein Occlusion trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Greater Houston Retina Research pipeline card: 8 registered trials from official public datasets.Report a data error.